Brief Title
Plasma EBV DNA Monitoring in Post-treatment NPC Patients
Official Title
Long-term Results of Plasma Epstein-Barr Virus DNA Monitoring In Nasopharyngeal Carcinoma After Curative Treatment
Brief Summary
Continuous regular monitoring of plasma EBV DNA in nasopharyngeal carcinoma (NPC) after treatment have rarely been investigated. The investigators try to analyze the long-term observational results (role in early relapse detection and impact on survival) in NPC patients after curative treatment.
Detailed Description
The investigators enrolled 441 NPC patients who had finished finished curative radiotherapy with/without chemotherapy and no recurrence/metastasis before entry this study from five hospitals in Taiwan. Blood samples were collected on the day of enrollment and monitored once every 2-3 months for plasma EBV DNA measurement. After long-term observation, we analyze the impact of continuous plasma EBV DNA monitoring on the early dection of tumor relapse and do risk grouping for survival analyses according to the blood test results.
Study Type
Observational
Primary Outcome
Time interval from the date of abnormal blood test to the date of clinically documented tumor relapse
Secondary Outcome
Overall survival (OS)
Condition
Nasopharyngeal Carcinoma
Study Arms / Comparison Groups
Patients with NPC after treatment
Description: All patients with NPC without distant metastases who receiving adequate RT dose
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Estimated Enrollment
441
Start Date
August 1, 2011
Completion Date
April 30, 2019
Primary Completion Date
December 31, 2013
Eligibility Criteria
Inclusion criteria - histologically-proven nasopharyngeal carcinoma without distant metastasis (M0) at initial presentation - finished curative radiotherapy (with/without chemotherapy) within 3 years Exclusion criteria - no occurrence of documented recurrence/metastasis before entry
Gender
All
Ages
18 Years - N/A
Accepts Healthy Volunteers
No
Contacts
Jin-Ching Lin, M.D.,PhD, ,
Location Countries
Taiwan
Location Countries
Taiwan
Administrative Informations
NCT ID
NCT03973723
Organization ID
CG11133
Responsible Party
Sponsor
Study Sponsor
Taichung Veterans General Hospital
Study Sponsor
Jin-Ching Lin, M.D.,PhD, Principal Investigator, Taichung Veterans General Hospital
Verification Date
June 2019